Prosecution Insights
Last updated: November 12, 2026
Application No. 17/996,728

HETERODIMERIC PROTEINS

Non-Final OA §112
Filed
Jul 24, 2023
Priority
Apr 22, 2020 — GB 2005879.8 +1 more
Examiner
LANDSMAN, ROBERT S
Art Unit
1647
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Petmedix Ltd.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
94%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1040 granted / 1278 resolved
+21.4% vs TC avg
Moderate +13% lift
Without
With
+13.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
63 currently pending
Career history
1328
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 1. Formal Matters A. In the response filed 7/27/26, Applicants elected the species of claim 1(a), drawn to positions 428 and 420. However, upon further review, all species have been examined. B. Claims 1, 3 and 35-50 are pending and are the subject of this Office Action. 2. Specification A. When a sequence is presented in a drawing, regardless of the format or the manner of presentation of that sequence in the drawing, the sequence must still be included in the Sequence Listing and a sequence identifier ("SEQ ID NO:X") must be used either in the drawing or in the Brief Description of the Drawings. See MPEP § 2422.02. In the instant application, a sequence identifier must be used for the sequences appearing in Figures 1 and 2. B. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors, embedded hyperlinks, or improperly referenced trademarks. Applicants’ cooperation is requested in correcting any errors of which Applicants may become aware. 3. Claim Objections A. It is noted that none of the claims have reference sequence identifiers (SEQ ID NOs). Based on this, it is believed that only one canine IgG CH3 domain is known to exist. Explanation is requested. While claims such as 1 are more generic, it is noted that claim 3, for example, identifies a specific amino acid residue at each recited position (e.g. E428), implying a known reference sequence. B. Claims 47 and 48 are objected to since “half life extending” should be hyphenated. 4. Claim Rejections - 35 USC § 112(a) – written description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-3 and 35-50 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. These are genus claims. The claims are drawn to a heterodimeric protein comprising various substitutions in two canine IgG CH3 domains. While adequate written description is provided for the positions recited in claim 1, as well as substitutions at each position, the claims recite “comprises”. Therefore, the substituted domains are not limited to these. While Applicants deserve some breadth, the issue is that, in theory, the entire domains can be altered and the specification does not provide adequate written description for this breadth. Other than comprising canine IgG CH3 domains, the specification and claims do not indicate what distinguishing attributes are shared by the members of the genus. Thus, the scope of the claims includes numerous structural variants, and the genus is highly variant because a significant number of structural differences between/among genus members is permitted. The specification and claims do not provide any guidance as to what changes should be made. Structural features that could distinguish compounds in the genus from others in the protein class are missing from the disclosure. No common structural attributes identify the members of the genus. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is what is needed. Since the disclosure fails to describe the common attributes or characteristics that identify members of the genus, and because the genus is highly variant, the positions in claim 1, alone, are insufficient to describe the genus. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, Applicant was not in possession of the claimed genus at the time the invention was made. While clearly the Examiner will consider arguments, amending the claims to recite, for example, and without adding new matter, "at least 95%", or in some manner restricting the number of substitutions (e.g. and without adding new matter – “no more than X additional substitutions”, where “X” is the number of substitutions), would obviate the rejection. However, any evidence supporting lower percentages will be considered (e.g. showing critical residues, sequence alignments). In addition, Applicants may amend the claims to indicate that the positions in claim 1 are the only ones that can be substituted. Again, however, some breadth will be considered. 5. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 35, which depends from claim 1, recites the limitation "the substitution at N387". There is insufficient antecedent basis for this limitation in the claim. 6. Conclusion No claim is allowable. Advisory information Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT S LANDSMAN whose telephone number is 571-272-0888. The examiner can normally be reached M-F 8 AM – 6 PM (eastern). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama, can be reached at 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /ROBERT S LANDSMAN/Primary Examiner, Art Unit 1647
Read full office action

Prosecution Timeline

Jul 24, 2023
Application Filed
Aug 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790373
CH1 DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME
4y 7m to grant Granted Nov 10, 2026
Patent 12780943
COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
3y 8m to grant Granted Nov 03, 2026
Patent 12782365
Antibody Combination Against Regenerating Islet-Derived Protein 1a And Detection Kit Comprising Same
2y 11m to grant Granted Nov 03, 2026
Patent 12774340
SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
3y 7m to grant Granted Oct 27, 2026
Patent 12774327
ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES
3y 0m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
94%
With Interview (+13.0%)
Low
PTA Risk
Based on 1278 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month